Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late, which are much ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $27.23, demonstrating a +1.04% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.13% gain on the ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hers provides medications for weight loss, hair loss, mental health, sexual health, and more. Here’s the lowdown on how it works and what it costs. Share on Pinterest Hers, a part of the Hims ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...